/ /

  • linkedin
  • Increase Font
  • Sharebar

    10 ophthalmic news stories you might have missed this week


    Video courtesy of National Eye Institute


    2. Aflibercept outperforms bevacizumab for DME with moderate or worse vision loss in NIH-funded trial; drugs perform similarly when vision loss mild

    Earlier this week, aflibercept (Eylea, Regeneron) was announced to provide greater gains in vision than for those receiving bevacizumab (Avastin, Genentech) with starting vision of 20/50 or worse in a 2-year clinical trial. The trial also tested results of ranibizumab (Lucentis, Genentech), which yielded similar gains as the other drugs in patients with 20/32 or 20/40 vision.

    Jolie Higazi
    Jolie is the Content Specialist for Ophthalmology Times. She can be reached at [email protected]

    New Call-to-action


    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available


    View Results